QIANJIANG YONGAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.05 CNY | +0.25% |
|
-2.19% | -17.69% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.46B 203M | Sales 2023 | 973M 135M | Capitalization | 2.88B 399M |
|---|---|---|---|---|---|
| Net income 2022 | 140M 19.39M | Net income 2023 | -12M -1.66M | EV / Sales 2022 | 1.57 x |
| Net cash position 2022 | 792M 110M | Net cash position 2023 | 946M 131M | EV / Sales 2023 | 1.99 x |
| P/E ratio 2022 |
22
x | P/E ratio 2023 |
-234
x | Employees | 887 |
| Yield 2022 |
0.95% | Yield 2023 |
1.02% | Free-Float | 66.14% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.25% | ||
| 1 week | -2.19% | ||
| Current month | -2.31% | ||
| 1 month | +26.18% | ||
| 3 months | +29.21% | ||
| 6 months | -20.14% | ||
| Current year | -17.69% |
1 week
7.95
8.17
1 month
6.518.73
Current year
5.4510.19
1 year
5.4511.21
3 years
5.4517.58
5 years
5.4517.58
10 years
5.4528.99
| Managers | Title | Age | Since |
|---|---|---|---|
Ren Gui Hong
CEO | Chief Executive Officer | 41 | 21-06-27 |
Yu Xi Wu
CHM | Chairman | 63 | 13-11-11 |
Sheng Jie Xiong
DFI | Director of Finance/CFO | 56 | 21-06-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Chen
FOU | Founder | 65 | 01-06-17 |
Yu Xi Wu
CHM | Chairman | 63 | 13-11-11 |
Hong Li Ding
BRD | Director/Board Member | 58 | 12-05-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 8.05 | +0.25% | 2,844,367 |
| 24-05-15 | 8.03 | -0.86% | 3,110,402 |
| 24-05-14 | 8.1 | +1.25% | 4,047,402 |
| 24-05-13 | 8 | -1.36% | 5,412,150 |
| 24-05-10 | 8.11 | -1.46% | 7,627,600 |
End-of-day quote Shenzhen S.E., May 15, 2024
More quotes
Qianjiang Yongan Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of taurine products. The Company operates through three main segments. The Taurine Products segment is mainly engaged in the research, development, manufacture and sales of taurine products, as well as the manufacture and sales of ethylene oxide. The Food Supplement segment is mainly involved in the research, development, manufacture and sales of dietary supplement, as well as the import and sales of overseas dietary supplement. The Health Field segment is mainly involved in the equity or industrial investment in health-related field.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.69% | 329M | |
| +32.36% | 694B | |
| +30.74% | 593B | |
| -1.60% | 371B | |
| +20.07% | 331B | |
| +6.04% | 290B | |
| +14.45% | 239B | |
| +10.07% | 209B | |
| -3.11% | 209B | |
| +9.27% | 169B |
- Stock Market
- Equities
- 002365 Stock
